Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experienceBhagirathbhai Dholaria, Olalekan O. Oluwole, Nasima Mehraban et al.|British Journal of Haematology|2022Cited by 25
Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and ConsiderationsKatie S. Gatwood, Olalekan O. Oluwole, Zahra Mahmoudjafari et al.|Clinical Hematology International|2024Cited by 21
Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trialBhagirathbhai Dholaria, Olalekan O. Oluwole, Shakthi Bhaskar et al.|Bone Marrow Transplantation|2025Cited by 9
Progressive multifocal leukoencephalopathy after CAR-T cell therapyMichael Montoya, David Morgan, Amy Messimore et al.|Bone Marrow Transplantation|2024Cited by 4
Outpatient Administration of Bispecific Antibody Therapy for Hematologic Malignancies: A Practical GuideKian J. Rahbari, Bhagirathbhai Dholaria, Raul del Toro Mijares et al.|JCO Oncology Practice|2025Cited by 3